Institutional Vehicles

Discover our offers that enable you to invest in young growing innovative companies (listed and unlisted) 

Fonds à destination des institutions

Découvrez nos offres vous permettant d’investir dans l’innovation, dans des entreprises jeunes et en développement, non-cotées et cotées.

TRUFFLE FINANCIAL INNOVATION FUND

Truffle Capital, a major and independent player in European Venture Capital, launched its first fund
dedicated to breakthrough technologies in the IT sectors, with a focus on the FinTech and InsurTech sectors.

■ The fund, which has a target size of €150 million, successfully completed its first closing
on November 15th 2017 at 70 M€.

■ The fund will invest in 12 to 15 companies (creation or early stage), each investment
of an amount between 5 and 20 M€.

Truffle Financial Innovation Fund is a vehicle entirely dedicated to the FinTech and InsurTech sectors. The fund’s target size is 150M€ and it will invest early stage in 12 to 15 companies, for amounts between 5M€ to 20M€ each. The fund will invest in young innovative companies that have the potential to become leaders in their respective markets in 3 to 6 years. The fund achieved its first closing at €70 million in November 2017.

Truffle Capital began investing in FinTech/Insurtech in 2011 and has since become one of the European leaders in these sectors. In 2015, Truffle launched France’s first incubator dedicated to start-ups in the FinTech and Insurtech sectors. The companies financed by Truffle Capital include Credit.fr (leader in crowdlending sold in June 2017 to Tikehau with a multiple of 2.8x), PayTop, a growing startup operating in the Payments sector, Smile & Pay, a provider of mobile payment card acceptance solutions, WizyPay, a prepaid digital services platform, Denyall, a provider of Security as a Service solutions for financial institutions (sold to Rohde and Schwartz in December 2016 with a multiple of 2.4x), Makazi, a platform of Big Data solutions for insurance companies, and most recently MoneyTrack, the first blockchain platform supported by the Fonds Unique Interministériel (FUI) aimed at revolutionizing directed payment.

The investment team performed exceptionally well in FinTech/InsurTech with an overall multiple of x3 in these sectors. This performance is linked to Truffle Capital’s “entrepreneur- investor” strategy and its ability to create or co-create companies from scratch based on disruptive technologies, with highly competent R&D teams. Truffle Capital systematically takes a majority or significant stake in its investments. This approach allows Truffle’s teams to be fully involved in the strategic and operational decision-making processes of each of the portfolio companies.

Truffle demonstrates the excellence of its unique expertise in blockchain, AI, Big Data, IOT and Cybersecurity technologies.

For subscription or documentation requests, please contact Amaury Daignes,

Investor Relations, at amaury@truffle.com

TRUFFLE BIOMEDTECH CROSSOVER FUND

Truffle Capital, a major and independent player in European Venture Capital, launched its first fund

dedicated to breakthrough technologies in the MedTech and BioTech sectors.

■ The fund, which has a target size of 200M€, successfully completed its first closing on
November 27, 2017 at 85 M€.

■ The fund will make 10 to 12 investments (creation from scratch or from spin-offs).
corporate or patent / unpublished intellectual property) with a performance target of
overall objective > X3 and a target IRR >20%.

The Truffle BioMedTech Crossover Fund is an investment vehicle dedicated to start-ups in the MedTech and BioTech sectors, with a predominance of MedTech (medical devices) and a clear focus on connected implants and prostheses. The fund, which aims at a target size of €200 million, made its first closing in November 2017 at €85 million.

Truffle Capital, through its previous funds, founded and became the main investor in Carmat (the first artificial heart in the world), as well as other disruptive companies such as Epygon, a highly differentiated company behind an extremely promising transcatheter mitral valve or Kardiosis, a company that develops a prosthesis targeting aortic aneurysms. In 2017, Symetis, a Swiss company that developed new transcatheter aortic valve implantation systems, was sold to Boston Scientific for $435 million, just before its IPO on Euronext Paris for €280 million. Another example of a successful exit is Vexim, the company that developed an innovative implant for the treatment of vertebral fractures via minimally invasive surgery, which was sold in October 2017 to Stryker Corporation for €183 million. Many other talented companies – such as Theraclion – are now moving into the commercialization phase.

Thanks to the experience of these successful investments (real and successful companies, excellent Cash In/Cash Out multiples), Truffle’s expertise in MedTech, BioTech and IT (application in connected objects such as prostheses), and through this new vehicle, Truffle’s ambition is to amplify its efforts and commitment to develop connected MedTech implants.
The strategy remains the same: identify and acquire intellectual property or unpublished patents throughout the world in the field of disruptive innovations, set up high-level management teams and boards, establish a rigorous and solid operational plan, have a hands-on approach, control the burn rate by avoiding budgetary restrictions, take advantage of French and European environments which encourage the development of innovation.

For subscription or documentation requests, please contact Amaury Daignes,

Investor Relations, at amaury@truffle.com

Truffle Capital

Contact Truffle Capital

6 + 2 =

BUREAU

5 Rue de la Baume, 75008 Paris, France
Tel: +33 1 82 28 46 00

EMAIL

contact@truffle.com

OUR WEBSITES

Truffle Capital

5 Rue de la Baume 75008 Paris France
Tel: +33 1 82 28 46 00
Email: contact@truffle.com

© 2018 Truffle Capital

Truffle Capital 2018

Social Networks

 
4685558dc1d1873359657876233e0853HHHHHHHHHHHHHHHHHHHHHHHHHH